SEC Filings

Form 10-Q
EXICURE, INC. filed this Form 10-Q on 11/06/2018
Document Outline
Entire Document (2871.5 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - EXICURE, INC.
Page 3 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 4 - N/A
Page 5 - PART I - FINANCIAL INFORMATION
Page 6 - EXICURE, INC.
Page 7 - EXICURE, INC.
Page 8 - EXICURE, INC.
Page 9 - EXICURE, INC.
Page 10 - EXICURE, INC.
Page 11 - EXICURE, INC.
Page 12 - EXICURE, INC.
Page 13 - EXICURE, INC.
Page 14 - EXICURE, INC.
Page 15 - EXICURE, INC.
Page 16 - EXICURE, INC.
Page 17 - EXICURE, INC.
Page 18 - EXICURE, INC.
Page 19 - EXICURE, INC.
Page 20 - EXICURE, INC.
Page 21 - EXICURE, INC.
Page 22 - EXICURE, INC.
Page 23 - EXICURE, INC.
Page 24 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 25 - XCUR17
Page 26 - microin vitroin vivo,
Page 27 - Recent Developments
Page 28 - Results of Operations
Page 29 - Research and development expense
Page 30 - Interest expense
Page 31 - Comparison of the Nine Months Ended September 30, 2018 and 2017
Page 32 - Research and development expense
Page 33 - Interest expense
Page 34 - Operating activities
Page 35 - Funding Requirements
Page 36 - Contractual Obligations and Commitments
Page 37 - Item 4. Controls and Procedures.
Page 38 - N/A
Page 39 - PART II OTHER INFORMATION
Page 40 - Our therapeutic candidates are in early stages of development and may fail in development or suffer
Page 41 - Product development involves a lengthy and expensive process with an uncertain outcome, and results
Page 42 - We will need substantial additional funds to advance the development of our therapeutic candidates,
Page 43 - Our quarterly operating results may fluctuate significantly or may fall below the expectations of in
Page 44 - If third parties on which we depend to conduct our preclinical studies and clinical trials do not pe
Page 45 - We may not successfully engage in strategic transactions, including any collaborations we seek, whic
Page 46 - We face competition from entities that have developed or may develop therapeutic candidates for our
Page 47 - Any inability to attract and retain qualified key management and technical personnel would impair ou
Page 48 - If our therapeutic candidates advance into clinical trials, we may experience difficulties in managi
Page 49 - Price controls imposed in foreign markets may adversely affect our future profitability.
Page 50 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 51 - We are subject to European data protection laws, including the new EU General Data Protection Regula
Page 52 - Our current operations are concentrated in one location and any events affecting this location may h
Page 53 - We have incurred significant losses since our inception and expect to incur continued losses in the
Page 54 - Association for Molecular Pathology v. Myriad Genetics, Inc.
Page 55 - We currently license patent rights from Northwestern University and may in the future license patent
Page 56 - inter alia
Page 57 - If we fail to comply with our obligations under any license, collaboration or other agreements, we m
Page 58 - We may be subject to claims that we or our employees or consultants have wrongfully used or disclose
Page 59 - Risks Related to Government Regulation
Page 60 - Certain of our therapeutic candidates may require companion diagnostics in certain indications. Fail
Page 61 - N/A
Page 62 - Any therapeutics we develop may become subject to unfavorable pricing regulations, third party cover
Page 63 - N/A
Page 64 - The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, an
Page 65 - Our ability to obtain services, reimbursement or funding from the federal government may be impacted
Page 66 - Significant developments stemming from the United Kingdom s recent referendum on membership in the E
Page 67 - Our stock price may be volatile and purchasers of our common stock could incur substantial losses.
Page 68 - The future issuance of equity or of debt securities that are convertible into equity may dilute your
Page 69 - The employment agreements with our executive officers may require us to pay severance benefits to of
Page 70 - The designation of our common stock as a penny stock would limit the liquidity of our common stock.
Page 71 - Anti-takeover provisions in our charter documents and under the General Corporation Law of the State
Page 72 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 73 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 74 - Item 6. Exhibits.
Page 75 - SIGNATURES
Subdocument 2 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet